Tyler Trump
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tyler Trump has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Howard B. Goldman
Glickman Urological Institute, Cleveland Clinic
7 shared publications- Ahmad Haffar
Robert D. Jeffs Division of Pediatric Urology, James Buchanan Brady Urological Institutions, Johns Hopkins Hospital, Johns Hopkins Medical Institutions, Charlotte Bloomberg Children's Hospital, Baltimore, MD, USA
3 shared publications Amr A Elbakry
West Virginia University Department of Urology, Morgantown, WV, United States
3 shared publications- Amr Ahmed Elbakry
Department of Urology, NYU-Langone Health, New York, NY, USA
3 shared publications - Chad Crigger
Robert D. Jeffs Division of Pediatric Urology, James Buchanan Brady Urological Institutions, Johns Hopkins Hospital, Johns Hopkins Medical Institutions, Charlotte Bloomberg Children's Hospital, Baltimore, MD, USA
2 shared publications - Mohamad Salkini
Department of Urology, West Virginia University, West Virginia, USA
2 shared publications
Latest Publications
- Open Access
- 6 July 2026
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 21 (1) , 16
Prolapse Management in Patients in Childbearing Age
Purpose of Review: Pelvic organ prolapse (POP) in women of reproductive age presents unique challenges, requiring symptom relief while preserving fertility and uterine function. Although most cases occur postmenopausally, POP also affects younger women, mainly after vaginal delivery, especially with instrumental assistance, prolonged labor, or large infants. Additional risk factors include obesity, multiparity, and connective tissue disorders. Findings: Conservative options such as pelvic floor muscle training, biofeedback, and pessaries are typically first-line, with benefits in symptom improvement though evidence on prolapse severity remains mixed. Surgical alternatives, particularly uterine-sparing procedures like sacro-hysteropexy and native tissue repair, show favorable fertility outcomes and are increasingly performed laparoscopically or robotically. POP in pregnancy, while rare, can be managed effectively with conservative approaches to support positive outcomes. Summary: Management of POP in childbearing-age women requires an individualized, multidisciplinary approach, balancing conservative and surgical strategies with attention to reproductive goals and long-term health.
- 6 July 2026
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 21 (1) , 16
Open AccessProlapse Management in Patients in Childbearing Age
Purpose of Review: Pelvic organ prolapse (POP) in women of reproductive age presents unique challenges, requiring symptom relief while preserving fertility and uterine function. Although most cases occur postmenopausally, POP also affects younger women, mainly after vaginal delivery, especially with instrumental assistance, prolonged labor, or large infants. Additional risk factors include obesity, multiparity, and connective tissue disorders. Findings: Conservative options such as pelvic floor muscle training, biofeedback, and pessaries are typically first-line, with benefits in symptom improvement though evidence on prolapse severity remains mixed. Surgical alternatives, particularly uterine-sparing procedures like sacro-hysteropexy and native tissue repair, show favorable fertility outcomes and are increasingly performed laparoscopically or robotically. POP in pregnancy, while rare, can be managed effectively with conservative approaches to support positive outcomes. Summary: Management of POP in childbearing-age women requires an individualized, multidisciplinary approach, balancing conservative and surgical strategies with attention to reproductive goals and long-term health.
- Open Access
- 23 March 2026
- Published by Wiley in Neurourology and Urodynamics
- Vol. 45 (4) , 668-673
Seventy‐Five Years of NIH NIDDK Funding Has Increased Knowledge and Greatly Impacted Clinical Care
Seventy‐five years of research funding in benign Urology from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health has greatly advanced not only our knowledge of etiology and mechanisms of nononcologic urological conditions but has also advanced new technologies and treatments to improve clinical care. To illustrate the profound impact of NIDDK funding on research and clinical care, we undertook a survey of grants funded by NIDDK in the NIH Reporter website with a focus on translation of lower urinary tract health and disease research to the clinic. We highlight three examples of technologies whose development was funded by NIDDK: advanced artificial urinary sphincters, urodynamics, and neuromodulation. These examples demonstrate the difficulties in bringing innovations to clinical care, as well as successes. In addition, they illustrate how public investment through NIDDK funding can improve treatment outcomes, diagnostic capabilities, and provide multiple therapeutic options.
- 23 March 2026
- Published by Wiley in Neurourology and Urodynamics
- Vol. 45 (4) , 668-673
Open AccessSeventy‐Five Years of NIH NIDDK Funding Has Increased Knowledge and Greatly Impacted Clinical Care
Seventy‐five years of research funding in benign Urology from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health has greatly advanced not only our knowledge of etiology and mechanisms of nononcologic urological conditions but has also advanced new technologies and treatments to improve clinical care. To illustrate the profound impact of NIDDK funding on research and clinical care, we undertook a survey of grants funded by NIDDK in the NIH Reporter website with a focus on translation of lower urinary tract health and disease research to the clinic. We highlight three examples of technologies whose development was funded by NIDDK: advanced artificial urinary sphincters, urodynamics, and neuromodulation. These examples demonstrate the difficulties in bringing innovations to clinical care, as well as successes. In addition, they illustrate how public investment through NIDDK funding can improve treatment outcomes, diagnostic capabilities, and provide multiple therapeutic options.
- 20 October 2025
- Published by Springer Nature
- p. 161-172
Pain Related to Transvaginal Mesh Placed for Stress Urinary Incontinence and Pelvic Organ Prolapse
- 20 October 2025
- Published by Springer Nature
- p. 161-172
Pain Related to Transvaginal Mesh Placed for Stress Urinary Incontinence and Pelvic Organ Prolapse
- Open Access
- 31 May 2025
- Published by Springer Nature in International Urogynecology Journal
- Vol. 36 (7) , 1517-1521
Same Day Discharge with Vaginal Packing Following Pelvic Floor Reconstruction: An Analysis of Safety and Healthcare Utilization
Introduction and hypothesis: Vaginal packing is sometimes placed during pelvic floor reconstructive surgery to aid with hemostasis. Historically, these patients were admitted overnight. In the interest of moving patients safely and efficiently through the discharge process select patients are discharged home with vaginal packing. The objective of this study is to assess healthcare utilization and safety among patients discharged with packing. Methods: Retrospective review of patients undergoing pelvic organ prolapse (POP) surgery by a single surgeon between 2016 and 2023. Patients were identified before and after the 2020 COVID pandemic as this marked a transition point where same day discharge became heavily emphasized. The historic cohort (group 1) represents patients admitted overnight with vaginal packing compared to those discharged home same day to remove their own packing (group 2). Healthcare utilization and complications were recorded in the first 30 days postoperatively. Results: Thirty-eight patients were identified in group 1 and 39 in group 2. Age, BMI, and estimated blood loss was similar. There were 20 total unplanned encounters with 10 in each group (p = 0.95). Unplanned encounters in group 1 were seven phone calls/messages, one office visit, and two ED visits compared to three phone calls/messages, five office visits, and two ED visits in group 2. Overall complication rate was similar with six in group 1 and seven in group 2 (p = 0.80). There were zero cases of retained packing. Conclusion: Patients may safely be discharged home with vaginal packing in place with similar rate of complications and healthcare utilization when compared to hospital admission.
- 31 May 2025
- Published by Springer Nature in International Urogynecology Journal
- Vol. 36 (7) , 1517-1521
Open AccessSame Day Discharge with Vaginal Packing Following Pelvic Floor Reconstruction: An Analysis of Safety and Healthcare Utilization
Introduction and hypothesis: Vaginal packing is sometimes placed during pelvic floor reconstructive surgery to aid with hemostasis. Historically, these patients were admitted overnight. In the interest of moving patients safely and efficiently through the discharge process select patients are discharged home with vaginal packing. The objective of this study is to assess healthcare utilization and safety among patients discharged with packing. Methods: Retrospective review of patients undergoing pelvic organ prolapse (POP) surgery by a single surgeon between 2016 and 2023. Patients were identified before and after the 2020 COVID pandemic as this marked a transition point where same day discharge became heavily emphasized. The historic cohort (group 1) represents patients admitted overnight with vaginal packing compared to those discharged home same day to remove their own packing (group 2). Healthcare utilization and complications were recorded in the first 30 days postoperatively. Results: Thirty-eight patients were identified in group 1 and 39 in group 2. Age, BMI, and estimated blood loss was similar. There were 20 total unplanned encounters with 10 in each group (p = 0.95). Unplanned encounters in group 1 were seven phone calls/messages, one office visit, and two ED visits compared to three phone calls/messages, five office visits, and two ED visits in group 2. Overall complication rate was similar with six in group 1 and seven in group 2 (p = 0.80). There were zero cases of retained packing. Conclusion: Patients may safely be discharged home with vaginal packing in place with similar rate of complications and healthcare utilization when compared to hospital admission.
- Open Access
- 1 April 2025
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 3 (4)
March 2025: Report on Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) 2025 Meeting
- 1 April 2025
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 3 (4)
Open AccessMarch 2025: Report on Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) 2025 Meeting
- Open Access
- 31 March 2025
- Published by Korean Continence Society in International Neurourology Journal
- Vol. 29 (1) , 10-16
Outcomes of Sacral Neuromodulation and Intradetrusor Onabotulinum Toxin in the Management of Stroke Associated Urinary Incontinence
Purpose: Urgency urinary incontinence (UUI) is a common finding in patients with a history of stroke or cerebrovascular accident (CVA). UUI is associated with impaired quality of life as well as increased morbidity, mortality, and need for institutionalization. Medical therapy is often limited by side effects and/or cost prohibitiveness. As a result, third-line therapy is often implemented. The objective is to determine the efficacy of sacral neuromodulation (SNM) and onabotulinum toxin (BTX) in the management of post-CVA UUI.Methods: Retrospective analysis was performed to identify patients with post-CVA UUI who underwent SNM or BTX at a large academic medical center. The primary outcome was patient symptom response to third-line therapy. Treatment response was determined using the global response assessment scale. Patients reporting >50% improvement were categorized as having significant response. Secondary endpoints were proportion of patients achieving total dry and duration of therapy for those achieving significant response.Results: One hundred seventy-seven patients were identified (95 BTX, 82 SNM). Patients in the BTX group were older (71.9 years vs. 67.4 years, P=0.02) with otherwise similar demographics. Rate of symptom improvement to >50% of baseline was similar between the groups (66% of BTX, 61% of SNM, P=0.46) as was rate of patients experiencing total dryness (24% of BTX, 16% of SNM, P=0.17). Among patients achieving significant improvement there was no difference in continuation of therapy between the BTX and SNM groups. Younger age was identified as a predictor of >50% symptom improvement (odds ratio, 0.96; P=0.04) and treatment discontinuation (hazard ratio, 0.97; P=0.04) in SNM. Most common adverse events were urinary tract infection in BTX (11%) and pain in SNM (4%).Conclusions: BTX and SNM show roughly equal efficacy in the management of post-CVA UUI with nearly two-thirds of patients achieving significant benefit.
- 31 March 2025
- Published by Korean Continence Society in International Neurourology Journal
- Vol. 29 (1) , 10-16
Open AccessOutcomes of Sacral Neuromodulation and Intradetrusor Onabotulinum Toxin in the Management of Stroke Associated Urinary Incontinence
Purpose: Urgency urinary incontinence (UUI) is a common finding in patients with a history of stroke or cerebrovascular accident (CVA). UUI is associated with impaired quality of life as well as increased morbidity, mortality, and need for institutionalization. Medical therapy is often limited by side effects and/or cost prohibitiveness. As a result, third-line therapy is often implemented. The objective is to determine the efficacy of sacral neuromodulation (SNM) and onabotulinum toxin (BTX) in the management of post-CVA UUI.Methods: Retrospective analysis was performed to identify patients with post-CVA UUI who underwent SNM or BTX at a large academic medical center. The primary outcome was patient symptom response to third-line therapy. Treatment response was determined using the global response assessment scale. Patients reporting >50% improvement were categorized as having significant response. Secondary endpoints were proportion of patients achieving total dry and duration of therapy for those achieving significant response.Results: One hundred seventy-seven patients were identified (95 BTX, 82 SNM). Patients in the BTX group were older (71.9 years vs. 67.4 years, P=0.02) with otherwise similar demographics. Rate of symptom improvement to >50% of baseline was similar between the groups (66% of BTX, 61% of SNM, P=0.46) as was rate of patients experiencing total dryness (24% of BTX, 16% of SNM, P=0.17). Among patients achieving significant improvement there was no difference in continuation of therapy between the BTX and SNM groups. Younger age was identified as a predictor of >50% symptom improvement (odds ratio, 0.96; P=0.04) and treatment discontinuation (hazard ratio, 0.97; P=0.04) in SNM. Most common adverse events were urinary tract infection in BTX (11%) and pain in SNM (4%).Conclusions: BTX and SNM show roughly equal efficacy in the management of post-CVA UUI with nearly two-thirds of patients achieving significant benefit.
- 4 March 2025
- Published by Elsevier in Clinics in Geriatric Medicine
- Vol. 41 (2) , 153-161
Overactive Bladder Medications in Geriatrics—Risks and Realities
- 4 March 2025
- Published by Elsevier in Clinics in Geriatric Medicine
- Vol. 41 (2) , 153-161
Overactive Bladder Medications in Geriatrics—Risks and Realities
- Open Access
- 10 February 2025
- Published by Elsevier in Continence
- Vol. 13
Sacral neuromodulation outcomes in the management of lower urinary tract symptoms in multiple sclerosis patients
- 10 February 2025
- Published by Elsevier in Continence
- Vol. 13
Open AccessSacral neuromodulation outcomes in the management of lower urinary tract symptoms in multiple sclerosis patients
- 26 September 2024
- Published by Elsevier in European Urology
- Vol. 87 (4) , 477
Re: Efficacy and Safety of TAS-303 in Female Patients With Stress Urinary Incontinence: A Phase 2, Randomized, Double-blind, Placebo-controlled Trial
- 26 September 2024
- Published by Elsevier in European Urology
- Vol. 87 (4) , 477
Re: Efficacy and Safety of TAS-303 in Female Patients With Stress Urinary Incontinence: A Phase 2, Randomized, Double-blind, Placebo-controlled Trial
- Open Access
- 12 September 2024
- Published by Elsevier in Continence
- Vol. 12
Robotic assisted laparoscopic total removal of retropubic sling mesh for pelvic pain
- 12 September 2024
- Published by Elsevier in Continence
- Vol. 12
Open AccessRobotic assisted laparoscopic total removal of retropubic sling mesh for pelvic pain